AZD3632
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AZD3632, covering 2026-04-24 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression [Phase 1, Phase 2]